At present, China's pharmaceutical industry is moving from the initial stage of erection to maturity
.
It is worth noting that in this context, specialization in the division of labor has become a necessary means to
improve efficiency and reduce costs.
Taking domestic innovative drug R&D enterprises as an example, concentrating limited resources on R&D and other advantageous links, and handing over the commercialization link to professional external forces, has become an efficient means
to achieve commercialization as soon as possible and achieve capital recovery under the premise of lowest possible cost.
For example, Innovent Biologics announced earlier that it has reached a multi-project strategic cooperation and licensing agreement with Sanofi to cooperate in the development of two high-potential anti-tumor drugs SAR408701 (Tusamitamab Ravtansine; Clinical development and commercialization of anti-CEACAM5 antibody-drug conjugate) and SAR444245 (non-α-biased IL-2) in China, including exploring a series of clinical studies in combination with PD-1 inhibitor dab ® (Cindilimab injection), aiming to accelerate the development and market access of innovative therapies for the benefit of cancer patients
in China.
In September, Simcere Pharmaceutical and Almirall, a long-established European pharmaceutical company, jointly announced that they have entered into a licensing agreement for a preclinical innovative drug developed by Simcere Pharmaceutical, under which Almirall will obtain exclusive rights to develop and commercialize the drug outside Greater China, and Simcere will receive a total milestone payment of up to US$492 million, including US$15 million down payment
.
In May, Kelun Pharmaceutical also said that its holding subsidiary, Kelun Botai, had licensed its biomacromolecular tumor project A (SKB264) with independent intellectual property rights to MSD for research, development, manufacturing and commercialization
outside China (China includes Chinese mainland, Hong Kong, Macau and Taiwan).
In addition, for multinational pharmaceutical companies trying to achieve good performance in the Chinese market, cooperation with professional commercialization platforms is becoming a common choice
for more multinational pharmaceutical companies.
This development trend can actually be seen
from the recent cooperation between Chinese and foreign pharmaceutical companies.
It is reported that some time ago, AstraZeneca signed a strategic cooperation agreement
with BAHEAL Pharmaceutical.
According to the agreement, BAHEAL Pharmaceutical will obtain the commercial operation rights
of AstraZeneca's hypoglycemic drug Anglizerza R (saxagliptin tablets).
The two parties hope that through this cooperation, access to drugs will be further improved, so that classic antidiabetic drugs can benefit more hospitals and patients
.
On August 16, BAHEAL Pharmaceutical also announced that it signed a renewal agreement
with Takeda (China) Investment Co.
, Ltd.
in Qingdao, China.
Relying on BAHEAL Pharmaceutical's professional online and offline market commercialization capabilities, the two parties will continue to deepen the commercialization cooperation
of Takeda China's various brand products, including Darkplon ® (lansoprazole enteric-coated capsules), Pantoloc ® (pantoprazole sodium enteric-coated tablets), and Putopin ® (lansoprazole oral collapse tablets).
In general, in order to strengthen and expand the R&D pipeline and accelerate the commercialization of products, the cooperation between domestic and foreign pharmaceutical companies is becoming more frequent, and the cooperation content also involves products, marketing and other aspects
.
In the future, under the multi-dimensional cooperation, the joint "going out" and "introduction" of Chinese and foreign pharmaceutical companies are expected to further accelerate
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
